| Literature DB >> 30108798 |
Kyle J Eastman1, Kyle Parcella1, Kap-Sun Yeung1, Katharine A Grant-Young1, Juliang Zhu1, Tao Wang1, Zhongxing Zhang1, Zhiwei Yin1, Brett R Beno1, Steven Sheriff1, Kevin Kish1, Jeffrey Tredup1, Adam G Jardel1, Vivek Halan1, Kaushik Ghosh1, Dawn Parker1, Kathy Mosure1, Hua Fang1, Ying-Kai Wang1, Julie Lemm1, Xiaoliang Zhuo1, Umesh Hanumegowda1, Karen Rigat1, Maria Donoso1, Maria Tuttle1, Tatyana Zvyaga1, Zuzana Haarhoff1, Nicholas A Meanwell1, Matthew G Soars1, Susan B Roberts1, John F Kadow1.
Abstract
The development of a series of novel 7-azabenzofurans exhibiting pan-genotype inhibition of HCV NS5B polymerase via binding to the primer grip site is presented. Many challenges, including poor oral bioavailability, high clearance, bioactivation, high human serum shift, and metabolic stability were encountered and overcome through SAR studies. This work culminated in the selection of BMS-986139 (43) as a preclinical candidate.Entities:
Year: 2017 PMID: 30108798 PMCID: PMC6072320 DOI: 10.1039/c6md00636a
Source DB: PubMed Journal: Medchemcomm ISSN: 2040-2503 Impact factor: 3.597